

**ASX Announcement**

**22 March 2024**

**Placement and Entitlement Offer to raise up to a total of  
approximately \$7.1 million – amended timetable**

**Melbourne, Australia – 22 March 2024:** Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) refers to its ASX announcement regarding the Placement and Entitlement Offer released on 20 March 2024.

The indicative timetable for the Placement and Entitlement Offer has been amended as below:

**Indicative Placement and Entitlement Offer Timetable**

<b>Event</b>	<b>Date</b>
Placement and Entitlement Offer announcement	20 March 2024
Lodgement of Prospectus with ASIC and ASX	25 March 2024
Allotment and issue of New Shares under Placement (other than the issue of 15 million shares to Mr Cubbin)	26 March 2024
Record Date	28 March 2024
Dispatch of letter advising of access to Prospectus, prospectus available online and Entitlement Offer opens	4 April 2024
Entitlement Offer closes	24 April 2024
Allotment and issue of New Shares under Entitlement Offer	2 May 2024
Expected normal trading of New Shares under Entitlement Offer	3 May 2024

Note: Dates / times are indicative and subject to change. All times / dates are in reference to Melbourne Time

**Authorisation & Additional Information**

This announcement was authorised by the Chairman of OncoSil Medical Limited.

<p>Mr Nigel Lange CEO &amp; Managing Director E: <a href="mailto:nigel.lange@oncosil.com">nigel.lange@oncosil.com</a> T: +49 30 300 149 3043</p> <p><b>Media &amp; Investor Enquiries</b> The Capital Network Julia Maguire P: +61 2 8999 3699 E: <a href="mailto:julia@thecapitalnetwork.com.au">julia@thecapitalnetwork.com.au</a></p>	<p>Mr Christian Dal Cin CFO &amp; Company Secretary E: <a href="mailto:c.dalcin@acclime.com">c.dalcin@acclime.com</a> T: +61 3 9824 5254</p>
--	--

## About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12<sup>th</sup> most common cancer in men and the 11<sup>th</sup> most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival<sup>1</sup>.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (<sup>32</sup>P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: [www.oncosil.com/](http://www.oncosil.com/)

---

1 [www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/](http://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/)